Hutchmed submits new drug application to US FDA for cancer treatment

(Alliance News) - Hutchmed (China) Ltd on Friday said it has completed the rolling submission of ...

Alliance News 31 March, 2023 | 11:15AM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - Hutchmed (China) Ltd on Friday said it has completed the rolling submission of a new drug application for its fruquintinib cancer drug to the US Food & Drug Administration.

The Hong Kong-based treatments of cancer and immunological diseases said the new drug application is supported by its global phase 3 multi-regional clinical trial, which was conducted in the US, Europe, Japan and Australia.

The FDA submission is for fruquintinib to be used to treat refractory metastatic colorectal cancer. Refractory cancer is when the disease does not respond to treatment. Metastatic cancer is when it spreads to distant parts of the body.

Chief Medical Officer Michael Shi said: "This FDA submission is a significant milestone for patients in the US with metastatic CRC, one of the most common and deadly cancers in the US and worldwide. Fruquintinib is an important treatment option for patients with metastatic CRC in China, where it has been available to patients since 2018."

The firm added that it intends to submit regulatory applications for the marketing of fruquintinib in Europe and Japan later in 2023.

Hutchmed shares rose 2.3% to 221.89 pence each in London on Friday afternoon.

By Harvey Dorset, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
HUTCHMED (China) Ltd 344.00 GBX -1.71 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures